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Abstract
Aims The aim of this systematic review is to gain insight into
the published experience on percutaneous closure of a post-
infarction ventricular septal rupture (VSR).
Method Relevant literature was obtained by MeSH-term
searches in the online search-engine PubMed. Articles pub-
lished in the last 10 years were included. Further filtering was
done by using search limits and individual article selection
based on the aims of this systematic review.
Conclusion Percutaneous closure is a potential technique in a
select group of patients. The presence of cardiogenic shock
and closure in the acute phase after VSR diagnosis are impor-
tant risk factors of mortality. Device implantation is in general
successful with few procedure-related complications. Reduc-
tion of the shunt fraction has been reported frequently. This
technique is a less invasive alternative to surgical treatment
and should be applied on a case-by-case basis.
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Introduction
Post-infarction ventricular septum rupture (VSR) is a rare
mechanical complication of an acute myocardial infarction
(AMI). Due to the use of aggressive antithrombotic medi-
cation and more efficient revascularisation therapy, the in-
cidence of post-infarction VSR has decreased from 1–2% to
0.25–0.31 % [1]. An acute left-to-right shunt following a
VSR may lead to acute haemodynamic deterioration. When
conservative treatment is applied, mortality rates are as high
as 87–100 % [2, 3]. Unfortunately, even surgical patch
repair has a high mortality of 47 % in the first 30 days after
closure [2]. To date, the American College of Cardiology
and American Heart Association (ACC/AHA) still advise
immediate surgical closure of the VSR, often combined
with (multiple) coronary artery bypass grafting [4]. Due to
the high mortality rate, less invasive alternative treatments,
such as the use of percutaneous occluders, have been inves-
tigated. This article gives an overview of recently published
experiences with the use of percutaneous occluders as a
treatment for VSR.
Search strategy
For this systematic review we used the search engine PubMed
to browse through the online database MEDLINE using the
following MeSH terms: [ventricular septal rupture] OR [ven-
tricular septal defect] AND [myocardial infarction] AND
[septal occluder device] OR [transcatheter] OR [percutane-
ous]. English case series published from 2002 onwards were
included. The last search took place in February 2013. Only
case series of ≥4 patients were included as we believed they
were less sensitive to a selection bias than pure case reports.
Other relevant articles were also included.
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Procedure
The technique of percutaneous closure of a VSR is based upon
the well proven and widely used percutaneous technique for
closing a congenital ventricular septal defect. Echocardiogra-
phy with colour Doppler is used to determine the size and
anatomy of the VSR. More detailed information about the
lesion could be obtained by other imaging methods, such as
computed tomography, but up till now only few case reports
have been published [5]. Indication for a surgical or a percu-
taneous closing technique should be on a case-by-case basis.
Selection of the occlusion device will be discussed later in this
article.
Cannulation of the femoral artery and femoral vein or
internal jugular vein is performed using the Seldinger tech-
nique. A guidewire is introduced into the artery, through the
aortic valve and is advanced through the VSR into the right
ventricle and pulmonary artery. A second snaring wire is
introduced through the vein to connect to the guidewire in
the pulmonary artery. By retracting the snared wires, the
guidewire now forms an arteriovenous (AV) loop.
An alternative method is by creating a venovenous (VV)
loop. In this method the cannulae are inserted in the femoral
and jugular vein. The initial guidewire, inserted via de femoral
vein, perforates through the atrial septum into the left heart
system. It then travels via the VSR into the right ventricle and
will be snared in the pulmonary artery. The procedure is at that
point the same as with the AV-loop method.
The delivery sheath is advanced from the venous side loop
over the guidewire through the VSR into the left ventricle.
Using fluoroscopy and/or echocardiography, correct position-
ing of the delivery sheath is confirmed. The guidewire is then
retracted leaving the delivery sheath in position. Once echo-
cardiographic confirmation of the necessary device size has
been achieved, the device is placed inside its catheter and
advanced through the VSR using the delivery sheath. The
distal disc is opened, the device is retracted, so that it will be
secured against the septal tissue at the side of the left ventricle.
The second proximal disc is opened by further retracting the
delivery sheath. Correct positioning of the device and closure
is confirmed by echocardiography and/or fluoroscopy. If
placement is satisfactory, the occluder is released. The proce-
dure is concluded by retracting the delivery sheath, guidewire
and cannulae.
VSR localisation and characteristics
An anterior or inferior AMImay lead to VSR formation due to
progressive septal tissue necrosis. The VSR diameter will
often increase over time until stabilisation, due to the scarring
of the surrounding tissue. Localisation is also an important
factor as an apical or perivalvular VSR might not be suitable
for percutaneous occlusion. When treating a perivalvular VSR
the device may interfere with valvular components [6, 7]. Due
to the presence of the ventricle free walls, an apically located
VSR might pose difficulties in correctly positioning the device,
thus making these VSR localisations more challenging [8].
The characteristics of a VSR greatly differ from those of a
congenital VSD. A congenital VSD is often symmetrical, has
strong borders and a relatively straight connection between the
left and right ventricle. In contrast, a VSR forms due to acute
ischaemic damage of the septum. As a result, a VSR is an
asymmetrical tear with unstable necrotic borders. In post-
mortem research VSR have been classified into simple versus
complex ruptures (Fig. 1). Simple VSRs are straight horizon-
tal septal canals whilst complex VSRs travel serpiginously
through the septum before exiting at a different level. The
majority of complex VSRs were the result of inferior AMI [9].
Percutaneous closure of a complex VSR is obviously more
challenging, but once a correct AV loop or VV loop is
achieved, device placement is possible.
Occluder devices
Based on the existing literature, a variety of devices for
percutaneous closure of a VSR have been used. These devices
are the atrial-septal-defect occluder (ASDo), muscular-
ventricular-septal-occluder (mVSDo) and recently a specific
post-infarction mVSDo occluder (PimVSDo) developed by
Amplatzer. The diameters of the applied devices were, on
purpose, significantly larger than the diameter of the VSR
measured using different imaging techniques. This
‘oversizing’ was particularly important when closures were
attempted in the acute phase. Some authors even stated that
the optimal diameter should be twice the size of the measured
VSR diameter or at least 10 mm larger [10, 11]. This prevents
incomplete closure or dislodging and embolisation of the
device due to continued septal necrosis. Occlusion in the
chronic phase demanded occluding devices that were only
moderately larger in diameter than the measured VSR. A
device sized 4–7 mm larger than the VSR should suffice [12].
It is not yet certain which occluder device is the best option
for the treatment of a VSR. However, only the use of ASDo
was not the best treatment option, especially in the acute
Fig. 1 Simple (a) versus
complex (b) ventricular septal
rupture
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phase. Due to the fact that the combination of a high pressure
gradient between the two ventricles and the high permeability
of an ASDo, it was unable to provide sufficient occlusion of
the VSR [2]. Some authors preferred the specific Amplatzer
PimVSDo. This device has a wider waist, larger disks and a
denser construction, which should lead to a faster occlusion
over a wider septal region. It is important to note that VSR
were often accompanied by accessory VSR. Therefore larger
discs were more likely to cover any accessory VSR [12–14].
Apart from the technical aspects, the personal preference of
the treating physician will also affect the decision as to which
occluder device will be used during the procedure.
Interval between diagnosis and occlusion
As mentioned earlier, the acute necrotic septum forms an
inadequate base for surgical patch repair. Therefore, despite
ACC/AHA guidelines, there is a tendency to defer surgical
treatment by 2–4 weeks. In this time the necrotic process will
stabilise and scarring of the surrounding tissue will occur,
which will form a better fundament for a successful fixation
of the patch. The decision as to whether deferring is feasible or
not should be based on the haemodynamic stability of the
patient. Patients will typically be treated with supportive med-
ication, an intra-aortic balloon pump (IABP) and/or mechan-
ical circulatory support (MSC) [11, 15].
Acute-phase occlusion was defined as closure within
<14 days after diagnosis of the VSR. In the acute phase, patients
are often critically ill and have high logistic EuroSCORES [16].
Despite high procedural success (50–86.2 %), haemodynamic
stabilisation is often not achieved, leading to a very high
residual mortality of 42–100 % [11, 16–19].
Treatment during the chronic phase was defined as ≥14 days
after diagnosis of the VSR. Occlusion was performed on hae-
modynamically more stable patients, weeks or even months
after VSR formation. Procedural success is high (71.4–100 %)
and coincides with a lower mortality rate of 20–38.9 % [12,
20–22]. Table 1 summarises the included case series.
Cardiogenic shock
Patients suffering from a VSR will frequently present with
cardiogenic shock (CS) due to an acute left-to-right shunt
complicating the initial AMI. The presence of CS is associated
with a tremendous increase in mortality. In the prospective
research of Thiele et al. [17], all VSRs were treated directly
after VSR diagnosis independent of the haemodynamic state.
The acute-phase mortality, in this specific research defined as
closure within 30 days after VSR diagnosis, in the CS popu-
lation was 86 % (n=12/14) increasing to 93 % (n=13/14) in
the chronic phase. In contrast, the non-CS population had a
mortality rate of 36 % (n=4/11) in the acute phase, which
remained the same in the chronic phase. This case series was
particularly useful due to the fact that all patients were directly
treated when the VSR was diagnosed, independent of haemo-
dynamic stability. This rules out any selection bias based on
treatment delay and shows the importance of controlling CS
before attempting VSR occlusion [17].












Assenza et al. (2013) [23] 30 – – Med: 27 d – 7/30
Maltais et al.(2009) [11] 12 12 0 Mean: 6,1 d – 5/12
Thiele et al. (2009) [17] 29 29 0 Mean: CS: 1 d 25/29 CS: 13/14
Mean: Non-CS: 3 d Non-CS: 4/11
Ahmed et al. (2008) [18] 5 2 3 Med: 50 d 4/5 2/5
Martinez et al. (2007) [10] 5 3 2 Mean: 6 4/5 1/5
Marinakis et al. (2007) [16] 8 6 2 – – 7/8
Bialkowski et al. (2007)
[19]
17 0 19 Mean: 8,9 w 14/19 3/19
Demkow et al. (2005) [22] 11 1 10 Mean: 15,4 d 10/11 3/11
Holzer et al. (2004) [24] 18 6 12 Med: 25 d 16/18 7/18
Szkutnik et al. (2003) [12] 7 0 7 Mean: 7,7 w 5/7 1/7
Goldstein et al. (2003) [20] 4 0 4 Mean: 58 d 3/4 1/4
Marshall et al. (2002) [21] 18 0 >10 – – 7/18
Chessa et al. (2002) [25] 12 3 9 – 10/12 –
Total 176 62 78 – 91/110 (82.7 %) 61/162 (37,7 %)
AMI acute myocardial infarction, VSR ventricular septum rupture, Med median, CS cardiogenic shock
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Indications
Percutaneous occlusion is a less invasive alternative to surgi-
cal treatment, thusmaking it especially valuable when surgical
closure is not indicated. It is important to state that percutane-
ous occlusion is an option in every case where the decision to
perform an intervention has been made, because transforma-
tion to the classic surgical approach is possible at any time.
This technique is most successful when performed in the
chronic phase after post-infarction VSR diagnosis. If shunts
remain or residual shunts form, placement of multiple devices
is possible. Percutaneous occlusion is also successful in pa-
tients who present with clinically significant residual shunting
in follow-up after initial successful closure [17, 21–23]. Oc-
clusion in the acute phase in haemodynamic unstable patients
had the aim of permanently closing the VSR or stabilising the
patient as a step-up approach to surgical treatment. Unfortu-
nately results were not clearly beneficial compared with sur-
gery. Percutaneous treatment of a VSR should always be
considered when a patient refuses surgical treatment.
Complications
AVSR differs greatly from a congenital VSD. Themechanism
of origin of the VSR often results in a more complex anatomy,
making complete closure difficult. Apart from that, the device
has to be placed in fragile necrotic tissue where every manip-
ulation can lead to an increase of the VSR diameter and device
displacement. Persistent left-to-right shunting can be caused
by progressive septal necrosis or by complications in relation
to device placement. The presence of such a residual shunt
differs greatly amongst the different authors (12.5–100 %)
[10–12, 18, 20].
When percutaneous treatment was performed, a variety of
procedure-related complications occurred: device embolisation,
left ventricle free wall rupture, cardiac arrhythmia, haematoma
at the puncture side, haemolysis and dislodging of the occlud-
ing device. Procedure-related complications did not occur fre-
quently and were rarely the direct cause of mortality.
Complications not related to the procedure were multiple
organ failure [11, 12, 16, 18], haemolytic anaemia [18, 24, 25]
and sepsis [16]. Mortality occurring in the long-term period
following intervention was often the result of one of these
complications.
Conclusion
Percutaneous closure of a VSR is a feasible and a relatively
safe technique when applied on carefully selected patients. In
general, the less invasive character makes it favourable over
surgical treatment. Device placement was overall successful
and is rarely complicated by procedure-related complications.
Complete occlusion was not always achieved but gross reduc-
tion in shunt fraction led to good results regarding mortality
and post-intervention haemodynamic stability, thus proving
its efficacy. Following diagnosis, when percutaneous occlu-
sion was applied in the acute phase (<14 days) mortality rates
varied strongly from 42 % to 100 %, despite high procedural
success (50–86.2 %). Better results were obtained with treat-
ment in the chronic phase (≥14 days), reducing the mortality
rates to 20–38.9 %. The most important risk factors
concerning mortality were the presence of cardiogenic shock
and treatment in the acute phase. Further research with a larger
patient populations is needed to assess the true value of
percutaneous occlusion in post-AMI VSR.
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